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stood. Here we aimed to explore the molecular and biochemical
mechanisms of ursodeoxycholic acid (UDCA) in modulating the
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Results: Short term UDCA administration stimulated BA
synthesis by reducing circulating ﬁbroblast growth factor 19
and farnesoid X receptor (FXR) activation, resulting in cholesterol
7a-hydroxylase induction mirrored by elevated C4 and
7a-hydroxycholesterol. Enhanced BA formation depleted hepatic
and LDL-cholesterol with subsequent activation of the key
enzyme of cholesterol synthesis 3-hydroxy-3-methylglutaryl-
CoA reductase. Blunted FXR anti-lipogenic effects induced
lipogenic stearoyl-CoA desaturase (SCD) in the liver, thereby
increasing hepatic triglyceride content. In addition, induced SCD
activity in vWAT shifted vWAT lipid metabolism towards
generation of less toxic and more lipogenic monounsaturated
fatty acids such as oleic acid.
Conclusion: These data demonstrate that by exerting FXR-an-
tagonistic effects, UDCA treatment in NAFLD patients strongly
impacts on cholesterol and BA synthesis and induces neutral lipid
accumulation in both liver and vWAT.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY license.Introduction
Obesity is a major risk factor for the development of type 2
diabetes, hypertension and dyslipidemia exerting adverse effects
on the liver. The prevalence of non-alcoholic fatty liver disease
(NAFLD), as hepatic manifestation and major complication of
obesity and the metabolic syndrome, is dramatically rising and
comprises a spectrum ranging from steatosis over non-alcoholic15 vol. 62 j 1398–1404
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steatohepatitis (NASH) to advanced ﬁbrosis/cirrhosis, ultimately
leading to liver cancer. NAFLD is found in over two thirds of the
obese population, regardless of diabetic status, and in more than
90% of morbidly obese individuals (>40 kg/m2 body mass index
(BMI)); NASH is diagnosed in 19% and almost 50% of these
individuals, respectively [1]. A key feature of NAFLD is the hepatic
accumulation of triglycerides (TGs) and free cholesterol. Expansion
of white adipose tissue (WAT) with increased lipolysis and ﬂux of
fatty acids (FAs) to the liver due to insulin resistance (IR) critically
links WAT dysfunction to NAFLD/NASH development [2].
In addition to their detergent properties in lipid digestion, bile
acids (BAs) serve as signaling molecules by activating dedicated
receptors such as the nuclear farnesoid X receptor (FXR) in the
liver and intestine, which impacts on BA and lipid metabolism
[3,4]. Upon FXR activation, BA homeostasis is maintained via a
negative feedback loop decreasing expression of cholesterol 7a-
hydroxylase (CYP7A1), the key enzyme in BA de novo synthesis,
which mediates the conversion of cholesterol into BAs. Hepatic
CYP7A1 is repressed by FXR-induced small heterodimer partner
(SHP) and by ﬁbroblast growth factor 19 (FGF19). In addition,
FXR stimulation lowers triglyceridemia and hepatic TG
deposition by reducing the expression of lipogenic genes and
their regulators including sterol regulatory element-binding pro-
tein-1c (SREBP1c), fatty acid synthase (FASN) and stearoyl-CoA
desaturase (SCD) [3]. Conversely, FXR deﬁciency in mice results
in marked hypertriglyceridemia as a result of low apolipoprotein
C-II and high apolipoprotein C-III, which reduces the interactions
of chylomicrons and very low density lipoproteins (VLDL) with
the lipoprotein lipase and their breakdown [5].
Ursodeoxycholic acid (UDCA) is currently used as ‘panacea’ for
pharmacological treatment for a wide range of hepatobiliary dis-
orders and has been shown to improve steatosis and inﬂamma-
tion in mice [6]. Taurine-conjugated UDCA reduced hepatic
steatosis and enhanced insulin action in mouse liver, muscle
and WAT [7] and enhanced hepatic and muscle insulin sensitivity
in obese humans [8].
Clinical studies with UDCA in NAFLD have generated results
raising questions about therapeutic mechanisms of BAs: While
two randomized placebo-controlled trials did not show overall
histological improvement including ballooning and inﬂammation
[9,10], a recent high-dose UDCA study attenuated hepatic IR [11].
Importantly, understanding the mechanism(s) of action of UDCA
may be instrumental for the development of more effective BA-
based therapies for NAFLD/NASH.
In the present study, we aimed to investigate potential effects
and underlying mechanisms of short term UDCA exposure on the
interplay between hepatic and visceral WAT (vWAT) metabolism
by analyzing; (i) BA and cholesterol homeostasis; (ii) biliary
transporter expression; and (iii) FA/lipid partitioning in morbidly
obese patients with NAFLD/NASH. We herein uncover numerous
mechanistically interrelated changes in serum parameters and
mRNA expression patterns of genes involved in BA, cholesterol
and lipid metabolism. Moreover, we provide a detailed lipidomic
proﬁle of liver and vWAT uncovering altered storing properties
upon UDCA administration.
Patients and methods
Study population
Patients with morbid obesity (BMI >35 kg/m2) scheduled for laparoscopic Roux-
en-Y gastric bypass surgery at Ersta Hospital, Stockholm, were asked toJournal of Hepatology 2015participate in a clinical pharmacodynamic study of the metabolic and molecular
effects of UDCA. All candidates completed a detailed questionnaire about the
patient’s history and life-style. A total of 40 well-matched patients were equally
randomized by drawing lots to treatment with UDCA, 20 mg/kg/day, for three
weeks (Ursofalk, Dr. Falk, Freiburg, Germany; kind gift of MEDA, Stockholm,
Sweden) or no medication (controls) before surgery. UDCA was administered
open-label in two daily doses until the day before surgery, i.e. the ﬁrst dose
was given after drawing blood on day 1, the last dose in the evening before sur-
gery on day 21. Liver, kidney, intestinal or metabolic diseases other than NAFLD/
NASH (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/gamma-
glutamyl transferase (cGT) <3  ULN) were exclusion criteria, as well as the use of
medications known to affect liver function and metabolism. Blood samples were
taken in the fasting state at 8:00 AM, and tissue samples by ultrasound dissector
during surgery. No day 21 serum samples were taken in the control group. Based
on a widely accepted histological scoring system [12], the lesions of NAFLD were
classiﬁed as fatty liver or steatohepatitis on liver biopsies after surgery by a board
certiﬁed pathologist (C.L.).
All participants provided written informed consent. The study protocol
(ClinicalTrials.gov NCT01548079) was approved the by Ethics Committee at
Karolinska Institutet (Dnr 2008/2:3) and the Swedish Medical Products agency
(EudraCT 2007-005531-28).
For more details, see Supplementary Materials and Methods.Results
Patient characteristics
Out of 40 randomized patients, 19 ﬁnished per protocol in the
UDCA and 18 in the control groups. Drop-outs were due to diar-
rhea in the UDCA, and pregnancy and minor intraoperative bleed-
ing in the control groups. Gender, age, BMI, liver function tests
and IR (estimated by HOMA-IR) did not differ between groups.
Compliance to UDCA (>95% in each patient randomized to
treatment) was conﬁrmed by pill counts and UDCA measurements
in serum. All participants had been instructed not to change their
dietary habits, thus, BMI increased during the study period, both
in UDCA (42.4 ± 5.1 kg/m2 to 43.2 ± 5.2 kg/m2, p <0.05) and con-
trol (40.6 ± 3.9 kg/m2 to 41.1 ± 3.7 kg/m2, p <0.05) groups.
Interestingly, histological analysis revealed a higher steatosis
grade (1.2 to 1.9, p <0.05) and thereby NAFLD activity score
(NAS) (1.9 to 2.5, p <0.05) in the UDCA treated patients compared
to untreated controls at the day of surgery. Baseline HOMA-IR
classiﬁed 18/19 UDCA and 15/18 control patients as insulin
resistant. Fasting glucose and HbA1c levels were normal in all
patients.
UDCA increased BA synthesis and cholesterol turnover
UDCA treatment resulted in reductions of serum AST, cGT, as
well as free FA, total and LDL-cholesterol (LDL-C), whereas TGs
increased (Table 1).
Upon UDCA, BAs increased 10-fold with UDCA enrichments
in the range of recently reported peak concentrations in
non-cholestatic subjects [13]. UDCA constituted 87.7 ± 3.7% of
total BAs, in equal amounts unconjugated or glycine-conjugated
(Supplementary Table 1). Of note, also the amounts of primary
BAs chenodeoxycholic acid (CDCA) and cholic acid (CA) increased
as their glycine-conjugates (Supplementary Table 1). Whereas
CDCA elevations may have resulted from intestinal and/or
hepatic epimerization of UDCA [14], the simultaneous increase
of CA indicated enhanced de novo synthesis.
We ﬁrst focused on changes in BA metabolism. Serum BA
precursors, 7a-hydroxy-cholesterol and 7a-hydroxy-4-cholesten-
3-one (C4), were increased (Table 1) and mRNA and protein
expression levels of CYP7A1 were higher in liver samples ofvol. 62 j 1398–1404 1399
Table 1. Serum parameters before and after UDCA treatment.
UDCA day 1 UDCA day 21 p value
Aspartate aminotransferase (U/L) 31.5 ± 12.0 23.0 ± 5.6 <0.05
Alanine aminotransferase (U/L) 46.0 ± 26.1 33.4 ± 12.4 n.s.
Gamma-glutamyl transferase (U/L) 48.1 ± 20.1 31.6 ± 12.7 <0.01
Total cholesterol (mM) 5.3 ± 1.2 4.9 ± 1.1 <0.05
LDL-cholesterol (mM) 3.2 ± 0.9 2.9 ± 1.1 <0.01
HDL-cholesterol (mM) 1.2 ± 0.2 1.2 ± 0.3 n.s.
Triglycerides (mM) 1.6 ± 0.8 2.1 ± 1.3 <0.05
Free fatty acids (mM) 0.63 ± 0.30 0.45 ± 0.20 <0.05
HOMA-IR 6.6 ± 3.9 5.8 ± 3.1 n.s.
FGF19 (pg/L) 83.1 ± 44.1 68.0 ± 46.5 <0.05
FGF21 (pg/L) 333.7 ± 271.2 352.0 ± 251.5 n.s.
7α-Hydroxycholesterol (μM) 0.11 ± 0.03 0.16 ± 0.05 <0.05
7α-Hydroxy-4-cholesten-3-one (μmol/mol cholesterol) 4.81 ± 2.56 8.74 ± 5.47 <0.05
LDL, low density lipoprotein; HDL, high density lipoprotein; n.s., not signiﬁcant.
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Fig. 1. UDCA alters key determinants of hepatic bile acid and cholesterol
homeostasis. (A)mRNAanalysis of bile acidbiosynthesismarkers. Controls: n = 18;
UDCA: n = 19. (B) Representative Western blots of CYP7A1, FXR and densitometry
(all samples) of protein levels relative to b-actin. Controls: n = 7; UDCA: n = 6. (C)
ABCD-assay indicating FXR activity. Controls: n = 7; UDCA: n = 6. (D) mRNA
analysis of cholesterol biosynthesis markers. Controls: n = 18; UDCA: n = 19. (E)
Representative Western blots of HMGCR, phosphorylation status of HMGCR
(HMGCRp), LDLR and densitometry (all samples). Controls: n = 7; UDCA: n = 6.
Mean values ± SD are expressed for all data. ⁄p 60.05, ⁄⁄p 60.01 vs. control group.
Research ArticleUDCA treated patients compared to controls (Fig. 1A and B). Thus,
BA biosynthesis was clearly stimulated upon UDCA. Notably,
negative feedback regulation of BA homeostasis via hepatic
FXR/SHP was not activated as reﬂected by unchanged SHP
mRNA expression (Fig. 1A) and decreased formation of FXR/RXR
DNA sequence complexes in the ABCD-assay (Fig. 1C). Rather,
BA synthesis was enhanced via decreased circulating FGF19
(Table 1), the inhibitor of CYP7A1 [15]. Further nuclear receptors
such as CAR and PXR remained unchanged on mRNA level upon
UDCA (data not shown).1400 Journal of Hepatology 2015Enhanced BA synthesis should affect cholesterol turn-over.
Indeed, we observed elevated hepatic mRNA levels of the tran-
scriptional regulator SREBP2 and its target, 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGCR), the rate-determining enzyme in
cholesterol synthesis (Fig. 1D) [16]. This was further sub-
stantiated by decreased HMGCR-phosphorylation (Fig. 1E).
UDCA treatment thus enhanced cholesterol synthesis as well.
Nevertheless, steady hepatic cholesterol ﬂux is suggested by
unchanged mRNA expression of the ATP-binding cassette
transporters ABCA1, ABCG1 mediating cholesterol efﬂux and
the biliary cholesterol transporters ABCG5 and ABCG8 (data not
shown). Notably, despite unchanged mRNA levels of the
LDL-receptor (LDLR), increased LDLR protein expression (Fig. 1E)
points towards increased cholesterol uptake from blood, which
could explain the observed decreases in total and LDL-cholesterol
upon UDCA treatment (Table 1).
Taken together, our results indicate that UDCA treatment
induced BA synthesis fueled by hepatic cholesterol. The liver
compensated cholesterol consumption via two pathways: i) the
induction of de novo cholesterol synthesis via SREBP2/HMGCR;
and ii) cholesterol uptake via LDLR.
Highly enriched UDCA does not alter hepatobiliary transporter
expression in NAFLD
Changes in BA ﬂux through the liver may affect BA signaling and
in turn, hepatic BA and lipid homeostasis. Therefore, we exam-
ined the effects of UDCA on hepatobiliary transporter expression.
No differences between untreated or UDCA treated groups were
observed in relation to RNA or protein expression of MRP2,
MRP3, MDR3 and BSEP (Supplementary Fig. 1A–C). Notably,
upregulation of MRP4 mRNA was not reﬂected by changes in pro-
tein expression (Supplementary Fig. 1A–C). Thus, UDCA did not
affect hepatobiliary transporter expression including NTCP and
OST-alpha/beta (data not shown) in morbidly obese patients, in
contrast to non-obese gallstone patients [17].
UDCA affects triglyceride and fatty acid partitioning in liver and
visceral white adipose tissue
To examine the impact of UDCA on lipid and cholesterol
partitioning along the liver-WAT axis, we performed tissue con-
centration measurements and lipid proﬁling.vol. 62 j 1398–1404
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Fig. 2. UDCA increases hepatic triglyceride formation and modulates hepatic
SCD expression. (A) Hepatic cholesterol and (B) triglyceride concentrations. (C)
Hepatic mRNA expression analysis of markers of lipid metabolism in morbidly
obese NAFLD patients. Control: n = 18; UDCA: n = 19. (D) Representative Western
blot and densitometry (all samples) of hepatic SCD relative to b-actin. Control:
n = 7; UDCA: n = 6. (E) mRNA expression of APOB and MTTP in NAFLD patients.
Control: n = 18; UDCA: n = 19. Mean values ± SD are expressed for all data.
⁄p 60.05, ⁄⁄p 60.01 vs. control group.
JOURNAL OF HEPATOLOGYHepatic cholesterol content (Fig. 2A) did not differ in UDCA
treated or untreated patients, despite changes in cholesterol syn-
thesis and uptake proteins. However, we observed an increase in
hepatic TG levels (Fig. 2B). FA proﬁling of the total liver FA pool
revealed an overall accumulation of FA species such as myristic
(MA, 14:0), palmitic (PA, 16:0), palmitoleic (16:1n7), stearic (SA,
C18:0) and oleic acids (OA, 18:1n9), whereas free FA species were
unaltered upon UDCA treatment (Table 2). We thus determined
the expression of lipid metabolism regulatory genes. SCD, the
enzyme catalyzing the formation of monounsaturated FAs such
as OA [18], was induced on mRNA and protein levels upon UDCA,
whereas expression of other lipogenic genes such as SREBP1c,
FASN and ACC1/2 remained unaltered (Fig. 2C and D). Moreover,
the microsomal TG transfer protein (MTTP) and apolipoprotein B
(ApoB), which are involved in VLDL export, did not differ between
the groups (Fig. 2E). Thus, UDCA likely stimulated hepatic FA
deposition as TG via hepatic SCD upregulation due to the absence
of FXR-mediated anti-lipogenic effects.
In vWAT of UDCA treated patients an increased TG load, again
without changes in cholesterol levels, was found (Fig. 3A and B).
Notably, UDCA treatment resulted in enrichment of OA in the
total FA fraction (Table 2), in line with the upregulation of SCD
mRNA (Fig. 3C). As observed in liver, expression of other lipogenic
genes such as FASN and SREBP1c did not differ between the
groups in vWAT (Fig. 3C).
Conversely, analysis of free FAs in vWAT revealed decreased
levels of free OA, together with MA, PA and SA upon UDCA treat-
ment (Table 2). Consistently, lower free FA concentrations were
also detected in the serum (Table 1). Additionally, FA transport
protein (FATP1) was reduced on mRNA level (Fig. 3C), which in
part could be attributed to restricted plasma free FA availability
(Table 1). The small amounts of protein in vWAT, limited our
expression analysis to mRNA levels. However, as a measure of
SCD activity, the ratio of unsaturated and saturated C16 and
C18 was calculated from total and free FAs. Except for C16 total
FA-ratio, desaturation processes and hence SCD activity were
induced upon UDCA treatment (Fig. 3D).Journal of Hepatology 2015Since OA is the preferential substrate for TG storage and pre-
vents lipotoxicity [19], our data suggests a shift in lipid metabo-
lism towards FA incorporation into visceral lipid droplets, which
was not related to changes in anti-lipolytic FGF21 serum levels
(Table 1). Unfortunately we could not address potential UDCA
effects on vWAT lipolysis due to virtually absent vWAT
enzymatic activity (data not shown).Discussion
In this pharmacodynamic study we analyzed liver tissue and
vWAT obtained during bariatric surgery from short term UDCA
treated and untreated morbidly obese NAFLD patients leading
to decreased FXR activity, stimulated cholesterol and BA synthe-
sis, hepatic lipid accumulation and altered lipid conversion in
vWAT. Here, we provide a comprehensive evaluation of mecha-
nistically interrelated metabolic alterations associated with
UDCA treatment, which may be most relevant for the develop-
ment of more effective BA mimetics for the treatment of NAFLD.
Stimulated BA synthesis during UDCA treatment, ﬁrst
described by Einarsson et al. [20], was later not consistently con-
ﬁrmed [21]. Furthermore, previous studies showed a con-
siderable increase in cholesterol and BA synthesis in obesity
[22]. We found that highly enriched UDCA enhances de novo BA
and cholesterol synthesis via induction of several BA and choles-
terol synthetic markers and enzymes such as C4, 7a-hydroxy-
cholesterol and CYP7A1 (for BAs) and hepatic SREBP2 and
HMGCR (for cholesterol) in morbid obesity. Since enhanced
cholesterol synthesis in turn fueled stimulated BA formation, no
net effect on hepatic cholesterol levels was observed. BAs sup-
press CYP7A1 via hepatic FXR/SHP and intestinal FXR/FGF19 sig-
naling pathways [23]. However, UDCA, which constituted almost
90% of BAs in our patients, has only low afﬁnity for and hence no
agonistic activity on FXR [24–28]. Indeed, ABCD-assays suggest a
decreased interaction of the FXR/RXR heterodimer with its DNA
binding sequence and hence reduced FXR activation upon
UDCA. Notably, this mechanism distinguishes UDCA from highly
potent FXR agonist obeticholic acid recently proven beneﬁcial in
NASH [29,30]. Moreover, our data suggest FXR-mediated reduc-
tion of intestinal FGF19 synthesis and secretion indicated by
decreased FGF19 serum concentrations, which are inverse to hep-
atic CYP7A1 expression levels. This further supports the concept
that UDCA abolishes endogenous FXR effects to an extent even
reaching FXR-antagonistic properties, reﬂected by increased
mRNA and protein expression of CYP7A1; by increased serum
levels of BA precursors 7a-hydroxycholesterol and C4, and pri-
mary BAs; as well as by lowered serum FGF19 concentrations,
decreased FXR/RXR DNA binding activities and blunted FXR
mediated anti-lipogenic actions. While such effects may be ben-
eﬁcial for cholesterol catabolism, FXR-antagonistic properties
could also explain UDCA’s limited clinical efﬁciency [9–11] in
comparison to FXR agonist obeticholic acid, which is associated
with increased insulin sensitivity upon 6 weeks treatment in dia-
betic NAFLD patients and improved liver histology but not IR
upon 72 weeks of administration in NASH patients [29,30].
Interestingly, UDCA, circulating in the enterohepatic system,
had no impact on hepatobiliary transporter expression in mor-
bidly obese patients, in contrast to a previous study in non-obese
gallstone patients [17], which might be related to approximately
tenfold higher total BA concentrations in the current study
cohort.vol. 62 j 1398–1404 1401
Table 2. Changes of fatty acid species in liver and vWAT upon UDCA.
FA Control TFA UDCA TFA p value Control FFA UDCA FFA p value
Liver
14:0 13.76 ± 6.92 27.22 ± 12.10 <0.001 2.5 ± 0.77 2.9 ± 0.91 n.s.
16:0 202.44 ± 84.96 312.93 ± 98.31 <0.01 39.84 ± 13.71 34.29 ± 8.08 n.s.
16:1n7 29.98 ± 17.09 54.60 ± 20.7 <0.001 2.12 ± 0.88 2.98 ± 0.79 n.s.
18:0 53.91 ± 8.37 63.10 ± 10.43 <0.01 32.68 ± 13.43 25.70 ± 13.1 n.s.
18:1n9 243.00 ± 113.73 425.02 ± 107.56 <0.001 19.84 ± 5.55 21.52 ± 6.36 n.s.
vWAT
14:0 28.5 ± 6.5 28.4 ± 6.9 n.s. 2.2 ± 1.6 0.37 ± 0.36 <0.01
16:0 215.1 ± 35.4 220.8 ± 27.1 n.s. 28.4 ± 22.3 4.29 ± 4.98 <0.001
16:1n7 73.9 ± 18.6 81.5 ± 15.2 n.s. 4.1 ± 2.8 2.82 ± 1.65 n.s.
18:0 26.7 ± 6.2 23.7 ± 5.4 n.s. 10.8 ± 7.9 0.65 ± 0.96 <0.001
18:1n9 430.1 ± 68.5 475.5 ± 56.0 <0.05 40.0 ± 28.2 19.3 ± 9.73 <0.001
18:1n11 63.6 ± 15.4 50.3 ± 11.3 <0.05 2.0 ± 1.4 1.20 ± 0.64 n.s.
Total fatty acid (TFA) and free fatty acid (FFA) species are relative to internal standards. n.s., not signiﬁcant.
0.02 
0.00 
0.04 
B C
D
R
el
at
iv
e 
m
R
N
A
 (f
ol
d)
 
* 
0.0 
0.5 
1.0 
1.5 
A
*** 
0.0 
0.5 
1.0 
Total FA 
vWAT 
cholesterol
vWAT 
triglycerides
FFA 
C
16
:1
n7
/C
16
:0
 
0 
10 
20 
30 
Total FA FFA 
C
18
:1
n9
/C
18
:0
 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
FA
SN
 
SC
D 
FA
TP
1 
** 
** * 
* 
SR
EB
P1
c 
Control UDCA 
μg
 c
ho
le
st
er
ol
/m
g 
vW
A
T 
μg
 T
G
/m
g 
vW
A
T 
Fig. 3. UDCA induces triglyceride formation and lipogenic gene expression in
visceral white adipose tissue (vWAT). (A) Measurement of cholesterol and (B)
triglyceride content in vWAT. (C) Relative mRNA expression of markers of de novo
lipogenesis and fatty acid (FA) transport in vWAT. (D) SCD activity calculated
according to C16:1/C16:0 and C18:1/C18:0 concentrations in total and free FA
obtained from lipid proﬁling. Control: n = 16; UDCA: n = 14. Mean values ± SD are
expressed for all data. ⁄p 60.05, ⁄⁄p 60.01, ⁄⁄⁄p 60.001 vs. control group.
Research ArticleRecently, upregulation of SREBP2 and HMGCR resulting in
increased serum LDL-C, and accumulating hepatic free choles-
terol and LDL-C was related to the pathogenesis and progression
of human NAFLD [31]. Despite enhanced cholesterol de novo syn-
thesis, our UDCA treated cohort featured decreased serum total-
and LDL-C concentrations. Thus, to meet the demands of induced
BA generation due to blunted FXR activation, cholesterol was also
mobilized from the periphery via LDLR since cholesterol catabo-
lism was compensated only in part by de novo synthesis.
Induced de-esteriﬁcation of cholesterol esters via neutral
cholesterol ester hydrolase (nCEH) has been linked to human
NAFLD [31]. However, our data suggest that short term UDCA
treatment does not affect hepatic free cholesterol and cholesterol
ester homeostasis, since expression of both acetyl-CoA
acetyltransferase 2 and nCEH, the enzymes regulating cholesterol
esteriﬁcation and de-esteriﬁcation [32], was similar in both1402 Journal of Hepatology 2015groups (data not shown). Based on these results, we conclude
that de novo synthesized cholesterol is directed towards BA syn-
thesis rather than cholesterol storage, consistent with unchanged
hepatic cholesterol levels.
Since WAT and liver lipid metabolism are tightly linked, dis-
turbed energy homeostasis in vWAT (e.g. increased FA ﬂux to
the liver as a result of IR) may exert deleterious effects on hepatic
FA turn-over [33]. Here we show that short term UDCA
administration, by replacing hydrophobic FXR-agonistic BAs
and thereby reducing FXR anti-lipogenic effects, impacts on lipid
conversion processes via elevated hepatic SCD expression.
Reduction of serum free FAs and induction of serum TGs resem-
ble lipid conversion events in vWAT and might be a consequence
of altered FA conversion processes via upregulated SCD expres-
sion in both liver and vWAT. Despite decreased FXR signaling,
direct UDCA effects on SREBP-1c, a known FXR target regulating
FASN [3], are missing. Unchanged SREBP-1c expression might
be explained by the gene’s high sensitivity to insulin [34], which
did not change within 21 days of UDCA treatment (data not
shown). Thus, we hypothesize that absent SREBP-1c repression
via FXR might represent one of the reasons for UDCA mediated
induction of hepatic lipid accumulation. Moreover, blunted
FXR-mediated anti-lipogenic effects are indicated by elevated
histology-proven steatosis scores and increased hepatic TGs
along with induced FA species in the total FA pool upon UDCA.
In contrast to other studies showing unaltered NAS, in which
obese patients were encouraged to lose weight [9,11], our
participants were instructed not to change their dietary habits
– possibly further promoting the adverse liver histology outcome.
Besides these potentially harmful properties, these changes could
also represent a hepatic mechanism counteracting injury from
exogenous lipid overﬂow, known to mediate liver injury and
apoptosis. Notably, conditions when SCD activity was induced
and monounsaturated FAs and TGs constituted the major lipid
species, were shown to attenuate lipotoxicity [19].
Lipid proﬁling of vWAT indicates that a combination of
increased OA (18:1n9) in the total FA pool and a corresponding
reduction of several lipid species in the free FA pool may con-
tribute to a potentially beneﬁcial shift towards improved lipid
storage and reduced lipotoxicity upon UDCA. Increased
expression of SCD appears to be the mechanism behind elevated
concentrations of monounsaturated OA (18:1n9) in the total FAvol. 62 j 1398–1404
Fig. 4. Overview of UDCA mediated effects in morbid obesity. UDCA decreases
intestinal FXR activation. Reduced circulating FGF19 levels induce CYP7A1
activity and BA formation. Compensation of stimulated cholesterol conversion
into BAs is regulated via LDL-C import and cholesterol de novo biosynthesis.
Elevated UDCA concentrations repress hepatic FXR activity, thereby decreasing
FXR mediated anti-lipogenic effects resulting in induced SCD expression and TG
accumulation. Hepatic TG-overload is secreted into the circulation and stored in
vWAT. Delivered free FAs (FFA) are converted into OA in the total fatty acid (TFA)
pool and TG formation occurs due to elevated SCD activity in vWAT. (This ﬁgure
appears in colour on the web.)
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pool. OA (18:1n9) accumulation along with the observation that,
except SCD, other lipogenic genes did not differ between the
groups, suggests an increase in FA synthesis, which was not
detected via mRNA analysis but by the accumulation of ﬁnal
products. The conversion of PA (16:0) and SA (18:0) deriving from
the free FA pool and representing preferential substrates for SCD
[35], could explain both their reduction in the free FA pool and
the elevation of OA (18:1n9) loads in the total FA pool. Due to
TG accumulation in vWAT, we hypothesize that expanded OA
(18:1n9) levels derived from the free FA pool might be preferen-
tially stored as TGs in lipid droplets in vWAT and thereby prevent
lipotoxic effects of other potentially harmful lipid species.
Elevated SCD activity in vWAT could be explained by surplus of
substrate for lipogenesis from hepatic lipid spill-over into the
circulation. However, the exact mechanism behind SCD activation
in vWAT upon short term UDCA treatment awaits further experi-
mental elucidation. Apart from increased OA (18:1n9), we identi-
ﬁed a decrease of vaccenic acid (VA, 18:1n11) in the total FA pool,
which is mainly provided by ruminant meat and dairy products
[36] and might be caused by less efﬁcient micelle formation and
dietary lipid absorption in the UDCA treated cohort [37].
Besides its function as a FA transport protein, FATP1 possesses
acyl-CoA synthetase activity, generating substrates for b-ox-
idation [38]. Therefore, the reduction of FATP1 mRNA levels in
vWAT suggests blunted visceral long chain free FA uptake and
decreased very long chain FA activation. However, genes linked
to b-oxidation such as CPT1a and AOX, did not differ between
groups in liver or vWAT (data not shown). Of note, loss of
FATP1 function in mice redistributes lipids fromWAT and muscle
towards the liver leading to hepatic TG accumulation [39]. This
might reﬂect an additional mechanism inducing hepatic TG accu-
mulation upon UDCA. Induction of alternative FA transport pro-
teins in vWAT such as CD36 and FATP4, potentially restoring FA
transport homeostasis, was not observed (data not shown).
The limitations of our study are the lack of placebo, of biopsies
before UDCA treatment and of feces sampling for BA measure-
ments. Due to restricted biopsy material, distinct investigations
are based on mRNA analysis; however key ﬁndings are validated
on protein level and are also supported by different biochemical
methods.
In summary, this unique pharmacodynamic study in morbid
obesity sheds new light on the therapeutic mechanisms and
potential limitations of UDCA in liver and vWAT and provides
novel mechanistic insights in the regulation of metabolic path-
ways in a population of uncomplicated NAFLD outlined in
Fig. 4. Short term UDCA treatment, by blunting FXR activity,
increases BA generation, thereby increasingly utilizing hepatic
cholesterol and subsequently inducing cholesterol de novo
biosynthesis and LDLR expression. Deﬁcient FXR activation also
increases SCD mediated hepatic TG formation. Understanding
SCD activation and the cytoprotective mechanism behind UDCA
action, counteracting accumulation of lipotoxic FA species in
vWAT, may facilitate the development of novel BA-based thera-
peutic strategies and/or expanding the use of UDCA.Financial support
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